Halozyme Therapeutics receives notice of allowance for second human enzyme

By Lisa Kerner

Erie, Pa., Feb. 13 - Halozyme Therapeutics, Inc. said the that U.S. Patent and Trademark Office has given a notice of allowance to both natural and recombinant forms of HTI-101, a second enzyme in Halozyme's pipeline.

The patent is licensed exclusively to Halozyme from the University of California, San Francisco, according to a company news release.

The new patent claims for HTI-101 are directed to a human enzyme normally found in the bloodstream which may prove useful for additional therapeutic applications.

The company is conducting pre-clinical work with HTI-101 in the fields of oncology and inflammation.

"We are pleased to add these new natural and recombinant composition of matter claims in the '283 patent to Halozyme's growing human enzyme intellectual property estate," Halozyme chief scientific officer Gregory Frost said in the release.

"This second enzyme can be readily channeled into our commercially validated molecular engineering systems and mammalian manufacturing processes, and fits nicely with Halozyme's demonstrated ability to develop and commercialize recombinant human enzymes."

Halozyme is a San Diego-based biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care and oncology markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.